Clinical Trial Detail

NCT ID NCT03135262
Title A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Idasanutlin + Rituximab + Venetoclax

Idasanutlin + Obinutuzumab + Venetoclax

Idasanutlin + Obinutuzumab + Rituximab + Venetoclax

Age Groups: senior adult

No variant requirements are available.